---
document_datetime: 2025-05-06 17:10:50
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lunsumio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lunsumio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8102737
conversion_datetime: 2025-12-26 12:25:31.471908
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lunsumio

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                    |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0014               | Renewal of the marketing authorisation. | 27/02/2025                          | 14/04/2025                                  | Annex II                         | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                       | renewal of the conditional MA for Lunsumio, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10999 /202406 | Periodic Safety Update EU Single assessment - mosunetuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/01/2025 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                          |
| IB/0013             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/10/2024 | n/a        |                       |                                                                                                                                            |
| PSUSA/10999 /202312 | Periodic Safety Update EU Single assessment - mosunetuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/07/2024 | 19/09/2024 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10999/202312. |
| R/0008              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/02/2024 | 19/04/2024 |                       |                                                                                                                                            |
| IB/0011/G           | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 17/04/2024 | 19/09/2024 | SmPC                  |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | procedure B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                |            |            |             |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a | 17/04/2024 | 19/09/2024 | Annex II    |                                                                                                                                            |
| PSUSA/10999 /202306 | Periodic Safety Update EU Single assessment - mosunetuzumab                                                                                                                                                                                                                                                                                                                                                      | 25/01/2024 | 21/03/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10999/202306. |
| IB/0007/G           | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                             | 19/10/2023 | 21/03/2024 | SmPC        |                                                                                                                                            |
| IB/0005             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure                                                                                                                                                                                                                                                                                                               | 10/10/2023 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | (including replacement or addition)                                                                                                                                                                                                             |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0006             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                    | 25/09/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/10999 /202212 | Periodic Safety Update EU Single assessment - mosunetuzumab                                                                                                                                                                                     | 06/07/2023 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0002/G           | This was an application for a group of variations. B.I.e.2 - Introduction of a post approval change management protocol related to the AS B.II.g.2 - Introduction of a post approval change management protocol related to the finished product | 12/05/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| R/0001              | Renewal of the marketing authorisation.                                                                                                                                                                                                         | 23/02/2023 | 19/04/2023 | Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Lunsumio, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other minor editorial changes have been implemented. |